Neoleukin Therapeutics, Inc. - Current Ratio

The Current Ratio as of June 2026 (TTM) for Neoleukin Therapeutics, Inc. (NLTX) is 13.08

According to Neoleukin Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 13.08. This represents a change of -20.85% compared to the average of 16.52 of the last 4 quarters.

Neoleukin Therapeutics, Inc. (NLTX) Historical Current Ratio (quarterly & annually)

How has NLTX Current Ratio performed in the past?

The mean historical Current Ratio of Neoleukin Therapeutics, Inc. over the last ten years is 17.11. The current 13.08 Current Ratio has changed 7.55% with respect to the historical average. Over the past ten years (40 quarters), NLTX's Current Ratio was at its highest in in the June 2019 quarter at 63.17. The Current Ratio was at its lowest in in the June 2018 quarter at 7.73.

Neoleukin Therapeutics, Inc. (NLTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Neoleukin Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Neoleukin Therapeutics, Inc. (NLTX) Average Current Ratio

How has NLTX Current Ratio performed in the past?

The current Current Ratio of Neoleukin Therapeutics, Inc. (NLTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Neoleukin Therapeutics, Inc. (NLTX) Current Ratio vs. Peers

How is NLTX’s Current Ratio compared to its peers?

Neoleukin Therapeutics, Inc.’s Current Ratio is greater than Lannett Company, Inc. (2.76), greater than DMK Pharmaceuticals Corporation (0.81), greater than Biora Therapeutics, Inc. (0.30), greater than ProSomnus, Inc. (1.00), greater than Turnstone Biologics Corp. (3.33), greater than Tvardi Therapeutics, Inc. (2.25), greater than COSCIENS Biopharma Inc. (8.01), greater than Omega Therapeutics, Inc. (3.35), greater than Channel Therapeutics Corporation (2.79), greater than Centogene N.V. (1.02),

Build a custom stock screener for Neoleukin Therapeutics, Inc. (NLTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neoleukin Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Neoleukin Therapeutics, Inc. (NLTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Neoleukin Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.